Sermorelin

Common questions about Sermorelin

What is sermorelin?

Sermorelin is the synthetic 1-29 fragment of human growth-hormone-releasing hormone (GHRH). It has historically been used clinically to stimulate endogenous GH release for the diagnosis and treatment of pediatric growth-hormone deficiency.

Is sermorelin FDA-approved?

Sermorelin acetate has historical FDA approval for the diagnosis and treatment of pediatric growth-hormone deficiency. The unbranded research-grade compound sold by peptide vendors is not the FDA-approved finished product and is intended for research use only.

What is the half-life of sermorelin?

Published clinical pharmacokinetic studies report a very short half-life of approximately 11–12 minutes after IV or subcutaneous administration, which is consistent with its native GHRH-fragment structure.

What dose of sermorelin is used in research?

Clinical dosing for the historical pediatric indication is documented in the original prescribing information. Pepticker does not publish a dosing recommendation — clinical use requires a prescription, and research protocols should follow the original published study.

What is sermorelin commonly stacked with?

In published research and vendor protocols, sermorelin is most often paired with a ghrelin-receptor agonist such as ipamorelin, mirroring the GHRH-arm + ghrelin-arm pattern used with CJC-1295 stacks.

How is sermorelin different from tesamorelin?

Both are GHRH analogs, but tesamorelin is stabilized for an extended half-life and is approved for HIV-associated lipodystrophy. Sermorelin is the unmodified GHRH 1-29 fragment with a much shorter half-life.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.